Related Experiment Video
Updated: Apr 20, 2026
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
Targeting microglia for the treatment of Alzheimer's disease
Patrick L McGeer1, Edith G McGeer
1University of British Columbia, Kinsmen Laboratory of Neurological Research , 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3 , Canada mcgeerpl@mail.ubc.ca.
Introduction:
Activated microglia are associated with the progression of Alzheimer's disease (AD), as well as many other neurodegenerative diseases of aging. Microglia are therefore key targets for therapeutic intervention.
Areas Covered:
β-amyloid (Aβ) deposits activate the complement system, which, in turn, stimulates microglia to release neurotoxic materials. Research has focused primarily on anti-inflammatory agents to temper this toxic effect. More recently there has been a focus on converting microglia from this M1 state to an M2 state in which the toxic effects are reduced and their phagocytic activity toward Aβ enhanced. Studies in transgenic mice have suggested a number of possible anti-inflammatory approaches but they may not always be a good model. An example is vaccination with antibodies to Aβ, which is effective in mouse models, but has repeatedly failed in clinical trials. Biomarker studies indicate that AD commences many years prior to clinical onset.
Expert Opinion:
A hopeful approach to a disease-modifying treatment of AD is to administer agents that inhibit the inflammatory stimulation of microglia or successfully convert them to an M2 state. However, any such treatment must be started early in the disease.
Insights
Targeting microglia, the brain's immune cells, offers a promising therapeutic strategy for Alzheimer's disease (AD). Early intervention is crucial for treatments aimed at reducing neuroinflammation and enhancing microglial function in AD.
Area of Science:
- Neuroimmunology
- Neurodegenerative Diseases
- Alzheimer's Disease Pathogenesis
Background:
- Microglia activation is implicated in Alzheimer's disease (AD) and other age-related neurodegenerative disorders.
- Microglia represent a critical therapeutic target for neurodegenerative diseases.
- Current research explores modulating microglial states (M1/M2) to mitigate neurotoxicity and enhance amyloid-beta clearance.
Purpose of the Study:
- To explore therapeutic strategies targeting microglial activation in Alzheimer's disease.
- To investigate methods for converting pro-inflammatory M1 microglia to an M2 state with reduced toxicity and enhanced phagocytic activity.
Main Methods:
- Review of existing research on microglial activation in AD.
- Analysis of therapeutic approaches, including anti-inflammatory agents and M1-to-M2 microglial conversion.
- Consideration of limitations in animal models for AD drug development.
Main Results:
- Beta-amyloid deposits trigger complement activation, stimulating microglia to release neurotoxic substances.
- Anti-inflammatory strategies and M1-to-M2 microglial conversion show potential for reducing neurotoxicity and improving Aβ clearance.
- Transgenic mouse models may not accurately predict clinical efficacy, as seen with Aβ antibody vaccination failures.
Conclusions:
- Modulating microglial inflammatory responses or promoting M2 state conversion presents a hopeful avenue for disease-modifying AD treatments.
- Early intervention is essential for the success of any therapeutic strategy targeting microglial pathways in AD.
- Biomarker studies suggest AD onset occurs years before clinical symptoms manifest, underscoring the need for early therapeutic strategies.
